Long-Term Outcomes of Patients Undergoing the Ross Procedure.

Aboud, Anas; Charitos, Efstratios I; Fujita, Buntaro; Stierle, Ulrich; Reil, Jan-Christian; Voth, Vladimir; Liebrich, Markus; Andreas, Martin; Holubec, Tomas; Bening, Constanze; Albert, Marc; Fila, Petr; Ondrasek, Jiri; Murin, Peter; Lange, Rüdiger; Reichenspurner, Hermann; Franke, Ulrich; Gorski, Armin; Moritz, Anton; Laufer, Günther; Hemmer, Wolfgang; Sievers, Hans-Hinrich; Ensminger, Stephan

doi:10.1016/j.jacc.2021.01.034

User: Guest

2021

Back
Back to start of result list
Permanent link for displayed object

Title:: Long-Term Outcomes of Patients Undergoing the Ross Procedure.
Document type:: Article; Journal Article; Observational Study
Author(s):: Aboud, Anas; Charitos, Efstratios I; Fujita, Buntaro; Stierle, Ulrich; Reil, Jan-Christian; Voth, Vladimir; Liebrich, Markus; Andreas, Martin; Holubec, Tomas; Bening, Constanze; Albert, Marc; Fila, Petr; Ondrasek, Jiri; Murin, Peter; Lange, Rüdiger; Reichenspurner, Hermann; Franke, Ulrich; Gorski, Armin; Moritz, Anton; Laufer, Günther; Hemmer, Wolfgang; Sievers, Hans-Hinrich; Ensminger, Stephan
Abstract:: BACKGROUND: Treatment of aortic-valve disease in young patients still poses challenges. The Ross procedure offers several potential advantages that may translate to improved long-term outcomes. OBJECTIVES: This study reports long-term outcomes after the Ross procedure. METHODS: Adult patients who were included in the Ross Registry between 1988 and 2018 were analyzed. Endpoints were overall survival, reintervention, and major adverse events at maximum follow-up. Multivariable regression analyses were performed to identify risk factors for survival and the need of Ross-related reintervention. RESULTS: There were 2,444 adult patients with a mean age of 44.1 ± 11.7 years identified. Early mortality was 1.0%. Estimated survival after 25 years was 75.8% and did not statistically differ from the general population (p = 0.189). The risk for autograft reintervention was 0.69% per patient-year and 0.62% per patient-year for right-ventricular outflow tract (RVOT) reintervention. Larger aortic annulus diameter (hazard ratio [HR]: 1.12/mm; 95% confidence interval [CI]: 1.05 to 1.19/mm; p < 0.001) and pre-operative presence of pure aortic insufficiency (HR: 1.74; 95% CI: 1.13 to 2.68; p = 0.01) were independent predictors for autograft reintervention, whereas the use of a biological valve (HR: 8.09; 95% CI: 5.01 to 13.08; p < 0.001) and patient age (HR: 0.97 per year; 95% CI: 0.96 to 0.99; p = 0.001) were independent predictors for RVOT reintervention. Major bleeding, valve thrombosis, permanent stroke, and endocarditis occurred with an incidence of 0.15% per patient-year, 0.07% per patient-year, 0.13%, and 0.36% per patient-year, respectively. CONCLUSIONS: The Ross procedure provides excellent survival over a follow-up period of up to 25 years. The rates of reintervention, anticoagulation-related morbidity, and endocarditis were very low. This procedure should therefore be considered as a very suitable treatment option in young patients suffering from aortic-valve disease. (Long-Term Follow-up After the Autograft Aortic Valve Procedure [Ross Operation]; NCT00708409).
Journal title abbreviation:: J Am Coll Cardiol
Year:: 2021
Journal volume:: 77
Journal issue:: 11
Pages contribution:: 1412-1422
Fulltext / DOI:: doi:10.1016/j.jacc.2021.01.034
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/33736823
Print-ISSN:: 0735-1097
TUM Institution:: Klinik für Herz- und Gefäßchirurgie (Prof. Lange)
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Klinik für Herz- und Gefäßchirurgie (DHM) (Prof. Krane)2021